Litcius/Paper detail

Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

Liying Ma, Xing Bian, Wenchu Lin

2021Journal of Experimental & Clinical Cancer Research20 citationsDOIOpen Access PDF

Abstract

An amendment to this paper has been published and can be accessed via the original article.

Topics & Concepts

OlaparibPARP inhibitorCancer researchDual (grammatical number)Lung cancerChemistryPoly ADP ribose polymeraseComputer scienceMedicineInternal medicineBiochemistryPhilosophyLinguisticsGenePolymeraseLung Cancer Research StudiesHistone Deacetylase Inhibitors ResearchCancer therapeutics and mechanisms
Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer | Litcius